Course Videos
What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?
Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?
What is the comprehensive spectrum of molecular alterations that whole exome NGS provides that are integral to precision-based treatment for lung adenocarcinoma?
Can you provide a specific patient example — in a patient with EGFR-positive NSCLC — where ctDNA may redirect treatment?
How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information? Why are the results from these two tests sometimes divergent in the same patient?
Among the platforms available for NGS comprehensive genomic profiling, what features do you look for when selecting an NGS platform? What do you use in your precision cancer clinic?
What are the validations demonstrating that larger molecular profiling panels — those that use NGS to interrogate several hundred genes and provide comprehensive genomic profiles— are superior to targeted or hot spot panels?
In what tumor subtypes — and based on what specific molecular targets (BRAF, EGFR, MEK, ALK-1 and others, including MSI) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates, ...
Using the FoundationOne Report as an example, can you explain what information should ideally appear on an NGS report and what interpretative dimensions of the report are necessary to optimize its clinical value as treatment roadmap?
Can you provide specific patient examples where longitudinal assessment with a combination of tissue-based NGS and ctDNA can provide a more detailed roadmap of targeted therapy?
There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?
What kind of specific, actionable information is contained on an NGS CGP report? In what context is hybrid capture-based NGS especially valuable at the front lines of precision cancer care?